Department of Kinesiology, Nutrition, and Dietetics, University of Northern Colorado, Greeley, CO 80639, USA.
Department of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT 84112, USA.
Nutrients. 2023 Sep 27;15(19):4173. doi: 10.3390/nu15194173.
The endocannabinoid system is active in nervous and immune cells and involves the expression of two cannabinoid receptor genes (CB1 and CB2), along with endogenous endocannabinoid ligands, 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide), and their synthetic enzymes. Cannabidiol (CBD) is a non-intoxicating exogenous cannabinoid agonist derived from plants that, at high doses, has received FDA approval as an anticonvulsant for epileptic seizures, and at low doses is marketed as a food-grade supplement for improved mental health, sleep quality, and immunological function. At present, the predominance of published CBD clinical research has focused on ameliorative or disease-specific intervention, with few trials investigating CBD effects in healthy populations.
This clinical study aimed to investigate the effects of 8 weeks of 50 mg oral CBD on mental health, sleep quantity and quality, and immune cell function in healthy, college-aged individuals. Twenty-eight participants (average age 25.9 ± 6.1 y) were randomized to receive either daily oral capsules of 50 mg of CBD (CB, = 14) or a calorie-matched placebo (CN, = 14). Participants completed pre- and post-intervention assessments, including anthropometric measurements, mental health surveys, sleep analysis, and immunological function assessments.
After completing the 8-week intervention, there were no significant changes in body weight and BMI (CN: 1.09 ± 0.89%: CB: 1.41 ± 1.07%), or body fat percentage (CN: 9.01 ± 7.51%: CB: 8.57 ± 7.81%), respectively (values are % change pre to post, > 0.05). There were also no significant differences between CB and CN groups with respect to mental health measures, sleep quantity, or circulating immunophenotype as a result of the intervention. However, the CB group experienced significant improvements in sleep quality measured objectively using a sleep questionnaire ( = 0.0023) and enhanced Natural Killer (NK) immune cell function assessed in situ ( = 0.0125).
Eight weeks of daily 50 mg CBD may improve sleep quality, and NK immunosurveillance in healthy, younger adults.
内源性大麻素系统在神经和免疫细胞中活跃,涉及两种大麻素受体基因(CB1 和 CB2)的表达,以及内源性内源性大麻素配体 2-花生四烯酰甘油(2-AG)和花生四烯酰乙醇胺(大麻素)及其合成酶。大麻二酚(CBD)是一种非成瘾性的外源性大麻素激动剂,来源于植物,高剂量时已获得 FDA 批准用于癫痫发作的抗惊厥治疗,低剂量时则作为改善心理健康、睡眠质量和免疫功能的食品级补充剂销售。目前,已发表的 CBD 临床研究主要集中在改善或特定疾病的干预上,很少有试验研究 CBD 在健康人群中的作用。
本临床研究旨在探讨 8 周 50mg 口服 CBD 对健康、大学生人群的心理健康、睡眠质量和数量以及免疫细胞功能的影响。28 名参与者(平均年龄 25.9 ± 6.1 岁)随机分为每日口服 50mg CBD 胶囊(CB,n=14)或热量匹配安慰剂(CN,n=14)。参与者完成了干预前后的评估,包括人体测量学测量、心理健康调查、睡眠分析和免疫功能评估。
完成 8 周干预后,体重和 BMI(CN:1.09±0.89%:CB:1.41±1.07%)或体脂百分比(CN:9.01±7.51%:CB:8.57±7.81%)均无显著变化(均为%变化,预至后, > 0.05)。干预后,CB 和 CN 组在心理健康测量、睡眠量或循环免疫表型方面也没有显著差异。然而,CB 组在使用睡眠问卷客观测量的睡眠质量方面有显著改善( = 0.0023),并增强了原位评估的自然杀伤(NK)免疫细胞功能( = 0.0125)。
8 周的每日 50mg CBD 可能改善健康、年轻成年人的睡眠质量和 NK 免疫监视。